基本信息
views: 1
Career Trajectory
Bio
My personal research focuses on molecularly targeted therapies of primary and metastatic CNS tumors with monoclonal antibodies and their fragments. Our study we conducted was with a molecule we discovered many years ago, the extracellular matrix molecule, Tenascin. We have treated over 150 malignant brain tumor patients with excellent results with a radiolabeled antibody we developed against Tenascin. We are collaborating with Dr. Ira Pastan at NIH to develop tumor-targeted therapies by fusing single fragment chain molecules from monoclonal antibodies or from naïve human libraries to the truncated fragment of pseudomonas exotoxin A. One example of this is the pseudomonas exotoxin conjugated to a single fragment chain antibody that reacts with wild type EGFR and EGFRvIII, two overexpressed proteins on glioblastoma. The immunotoxin, called D2C7-IT, is currently being investigated in an FDA dose-escalation study, in which patients undergoing treatment of this investigational new drug are showing positive responses. My laboratory is also working with Matthias Gromeier, creator of the oncolytic poliovirus - a re-engineered poliovirus that is lethal to cancer cells, but not lethal to normal cells. The oncolytic poliovirus therapeutic approach has shown such promising results in patients with glioblastoma, that it was recently featured on a on a special two-segment program of 60 Minutes. The next clinical step will be to combine both the virus and the immunotoxin with anti-PD1, an immune checkpoint blockade inhibitor and with anti-CD40, a fully human monoclonal antibody which converts tumor stimulant macrophages into tumor suppressive macrophages. We believe that regional tumor-targeted cytotoxic therapies, such as oncolytic poliovirus and the D2C7 immunotoxin, not only specifically target and destroy tumor cells, but in the process, initiate immune events that promote an in situ vaccine effect. That immune response can be amplified by human checkpoint blockade to engender a long-term systemic immune response that effectively eliminates recurrent and disseminated GBM cells. Ultimately, all three agents may be used together, providing different antigenic targets and cytotoxicity mechanisms.
Research Interests
Papers共 1078 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Satoshi Shiina,Masasuke Ohno,Fumiharu Ohka,Shunichiro Kuramitsu,Akane Yamamichi,Akira Kato,Kazuya Motomura,Kuniaki Tanahashi,Takashi Yamamoto,Reiko Watanabe, Ichiro Ito, Takeshi Senga, Michinari Hamaguchi, Toshihiko Wakabayashi, Mika K. Kaneko,Yukinari Kato,Vidyalakshmi Chandramohan,Darell D. Bigner,Atsushi Natsume
openalex
crossref(2023)
Elizabeth A. Reap,Carter M. Suryadevara,Kristen A. Batich,Luis Sanchez-Perez,Gary E. Archer,Robert J. Schmittling,Pamela K. Norberg,James E. Herndon,Patrick Healy,Kendra L. Congdon,Patrick C. Gedeon,Olivia C. Campbell,Adam M. Swartz,Katherine A. Riccione,John S. Yi,Mohammed K. Hossain-Ibrahim,Anirudh Saraswathula,Smita K. Nair,Anastasie M. Dunn-Pirio,Taylor M. Broome,Kent J. Weinhold,Annick Desjardins,Gordana Vlahovic,Roger E. McLendon,Allan H. Friedman,Henry S. Friedman,Darell D. Bigner,Peter E. Fecci,Duane A. Mitchell,John H. Sampson
crossref(2023)
Eric M. Thompson,Daniel Landi,Michael C. Brown,Henry S. Friedman,Roger McLendon,James E. Herndon II,Evan Buckley,Dani P. Bolognesi,Eric Lipp,Kristin Schroeder,Oren J. Becher,Allan H. Friedman,Zachary McKay,Ashley Walter,Stevie Threatt,Denise Jaggers,Annick Desjardins,Matthias Gromeier,Darell Bigner,David M. Ashley
LANCET CHILD & ADOLESCENT HEALTHno. 7 (2023): 471-478
crossref(2023)
crossref(2023)
crossref(2023)
Load More
Author Statistics
#Papers: 1079
#Citation: 100781
H-Index: 132
G-Index: 303
Sociability: 8
Diversity: 3
Activity: 57
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn